// App-Quantinova.ai

: Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis (AD) Among Adults With Moderate-to-Severe AD Treated with Upadacitinib

Researchers

Presenter

  • Shawn G Kwatra

Principal Investigators

  • Marjolein De Bruin-Weller

  • Peter Lio

  • Mette Deleuran

  • Sarah Ofori

  • Henrique D Teixeira

  • Brian Calimlim

  • Yingyi Liu

  • Stephen Weidinger

Medical Centers

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

  • University Medical Center Utrecht, Utrecht, Netherlands

  • Feinberg School of Medicine, Northwestern University, Chicago, IL

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • AbbVie, Inc., North Chicago, IL

  • Department of Dermatology and Allergy, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany

Locations

  • United States

  • Denmark

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Dermatology

Disease

  • Atopic Dermatitis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved